Clinical trials: Major Depression With Psychotic Features
Major Depressive Disorder With Psychotic Features
Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms
The purpose of this study is to compare the efficacy and tolerability of Seroquel monotherapy for the treatment of Major Depression with Psychotic features with Seroquel plus Selective Serotonin Reuptake Inhibitor.
- Trial name
- Seroquel (NCT00955474)
- Testing
- Quetiapine, escitalopram, Sertraline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Prodromal Schizophrenia, Psychotic Disorders
Psychosis: Early Detection, Intervention and Prevention
The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders.
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
- Trial name
- EDIP (NCT01597141)
- Testing
- Family-aided Assertive Community Treatment, Enhanced standard treatment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth
Depressive Disorders, Psychotic Disorders
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized…
- Conditions
- Depressive Disorders, Psychotic Disorders, Depression
- Trial name
- NCT00844922
- Testing
- SCH 900636
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Schizoaffective Disorder
Academic-Community EPINET (AC-EPINET)
The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH) versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month, randomized trial.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features
- Trial name
- AC-EPINET (NCT04497857)
- Testing
- Coordinated Specialty Care (CSC)
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Indiana University
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Major Depression With Psychotic Features
Treatment of Major Depressive Disorder With Psychotic Features.
The purpose of this study is to determine the safety and efficacy of risperidone monotherapy in the treatment of psychotic depression.
- Trial name
- NCT00174590
- Testing
- risperidone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rush University Medical Center
Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features
Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features
Studies have shown that people with certain disorders have an increased risk of developing a condition called Metabolic Syndrome (MS).
- Conditions
- Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
- Trial name
- NCT01310140
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00208156
- Testing
- Mifepristone
- Where
- 13 sites in United States
- Volunteers
- 87 people
- Sponsor
- Corcept Therapeutics
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Bipolar Disorder
Early Detection and Intervention for the Prevention of Psychosis
EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States.
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
- Trial name
- EDIPP (NCT00531518)
- Testing
- aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
- Where
- 6 sites in United States
- Volunteers
- 292 people
- Sponsor
- MaineHealth
Major Depressive Disorder, Psychotic Disorders
Safety Study of ORG 34517 for Major Depression With Psychotic Features
Patients suffering from Major Depressive Disorder with Psychotic features who have received no changes in their medications in the previous two weeks will receive "usual" treatment of antidepressants, antipsychotics and/or mood…
- Trial name
- NCT00226278
- Testing
- ORG 34517
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features
Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy
This Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who…
- Trial name
- NCT07781293
- Testing
- Lurasidone, Background Antidepressant Therapy
- Volunteers
- 364 people
- Sponsor
- Bukwang Pharmaceutical
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Psychotic Depression, Severe Major Depression With Psychotic Features
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by…
- Conditions
- Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
- Trial name
- NCT00637494
- Testing
- mifepristone
- Where
- 42 sites in United States
- Volunteers
- 292 people
- Sponsor
- Corcept Therapeutics
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Recent-Onset Psychosis, Schizophrenia
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
The goal of this study is to determine whether pairing multifamily group psychoeducation with cognitive remediation may facilitate improved outcomes among individuals with recent-onset psychosis.
- Conditions
- Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features
- Trial name
- NCT01196286
- Testing
- Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Schizophrenia, Schizoaffective Disorder
Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
This twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
- Trial name
- NCT00179062
- Testing
- olanzapine versus risperidone
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Vanderbilt University
Schizophrenia, Schizoaffective Disorder
Impact of Medication Education on Adherence and Side Effects
Severe mental disorders such as schizophrenia, bipolar disorder, and psychotic depression often require long-term or lifelong medication treatment.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depressive Disorder With Psychotic Features
- Trial name
- MED-ADHERE (NCT07374588)
- Testing
- Medication Education Program, Routine Psychiatric Inpatient Care
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Cumhuriyet University
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics